Account
Newsletter
15.03.2023
PMA Insights: Week 11

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Insider Insights
22.02.2023
NICE announces the development of a new rapid revi...

New process to assess clinical and cost-effectiveness of COVID-19 treatments to get these medicines ...

Read more
Insider Insights
17.02.2023
Spain’s Ministry of Health copies NICE, and ...

Spain will ask pharmaceutical companies to submit their economic evaluation studies to reviewed late...

Read more
Insider Insights
25.01.2023
AstraZeneca/Daiichi Sankyo’s Enhertu has been re...

NICE have recommended Enhertu for the treatment of HER2-positive breast cancer within a managed acce...

Read more
Newsletter
16.11.2022
PMA Insights: Week 46 SPECIAL EDITION ISPOR 2022 R...

We summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...

Read more
Insider Insights
18.10.2022
UK Agencies join with International HTA Partners f...

A cross-border alliance of health technology assessment (HTA) agencies has been announced by the Can...

Read more
Publications
12.10.2022
ISPOR 2022: Do manufacturers still see value in su...

Our research is aimed at identifying trends in terminated appraisals in relation to therapeutic area...

Read more
Insider Insights
19.07.2022
NICE provides detail on Early Value Assessment

NICE provided more detail into how the process will work, with the early value assessments providing...

Read more
Insider Insights
13.07.2022
NICE expands access of Tremfya in England and Wale

The HTA initially recommended Tremfya as a treatment option for adults with active psoriatic arthrit...

Read more
Insider Insights
23.06.2022
NICE publish their new real world evidence framewo

NICE have been clear that this framework should not be interpreted as minimum standards for real-wor...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.